Emergent BioSolutions Inc. — Director's Dealing 2017

Mar 3, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-02-28

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-28	Common Stock	M	9722	—	Acquired	1658795	Direct
2017-02-28	Common Stock	F	2659	$30.63	Disposed	1656136	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-28	Restrictive Stock Units	$	A	29382	Acquired		Common Stock (29382)	Direct
2017-02-28	Restrictive Stock Units	$	M	9722	Disposed		Common Stock (9722)	Direct
2017-02-28	Employee Stock Option (right to buy)	$30.63	A	58747	Acquired	2024-02-27	Common Stock (58747)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4344250	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange act or otherwise, except to the extent of his pecuniary interest therein.

F3: Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, LLC, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, LLC for purposes of Section 16 of the Exchange act or otherwise, except to the extent of his pecuniary interest therein.

F4: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by continuing employees. Accordingly, Mr. El-Hibri, as a continuing Emergent employee with equity awards issued prior to the Spin-off, received an equitable adjustment to the number and grant price of his restricted stock units.

F5: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.

F6: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.

F7: On February 28, 2017, Mr. El-Hibri was granted 58,747 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.